Arbutus Biopharma Corporation - Common Stock - fluxo de caixa (NASDAQ:ABUS)

Financials

Fluxo de caixa operacional -51.44 M-67.53 M-35.36 M-85.94 M-64.85 M-39.64 M -34.36 M Fluxo de caixa de investimento -14.91 M-12.68 M-74.94 M50.77 M22.95 M15.58 M 6.43 M Fluxo de caixa de financiamento 86.75 M137.24 M31.81 M30.65 M52 M5.72 M 14.56 M Fluxo de caixa livre -51.44 M-67.53 M-35.36 M-85.94 M-64.85 M-39.64 M -34.36 M

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

ABUS

Financials

Arbutus Biopharma Corporation - Common Stock

Notícias

Lucro da Arbutus Biopharma superou projeções por $0,91; receita supera estimativas

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Moderna's Quarterly Earnings Preview: What You Need to Know

Lucro da Arbutus Biopharma superou projeções por $0,02; receita supera estimativas

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Chardan reitera recomendação de compra para Arbutus Biopharma após acordo com Moderna

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Ações da Moderna atingem máxima de 52 semanas a US$ 55,22

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang